Zymeworks IPO

4/28/2017

IPO

$58,500,000

We intend to use the net proceeds of this offering as follows: approximately $20.0 million to $30.0 million to fund clinical development expenses for ZW25 through our ongoing adaptive Phase 1 clinical trial (approximately $10.0 million to $15.0 million), including monotherapy and combination therapy cohort expansion arms and additional product candidate manufacturing (approximately $10.0 million to $15.0 million); approximately $5.0 million to fund clinical development expenses for ZW33 through our planned Phase 1 clinical trial and additional product candidate manufacturing; approximately $7.8 million to repay outstanding principal and interest under the Perceptive Facility which matures on June 2, 2020 and which we have used for working capital and general corporate purposes; advances under the Perceptive Facility bear interest at LIBOR + 10% annually, with LIBOR to be a minimum of 1%; we intend to repay the Perceptive Facility immediately after June 2, 2017; repayment at this time i

Publicly-held

Biopharmaceutical

1385 West 8th Ave. 540
Vancouver BC, V6H 3V9
Canada

Zymeworks (NYSE: ZYME) is committed to the development of best in class antibody and protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks combines proprietary molecular simulation technology with high performance computing to design and optimize protein therapeutics.